Arbutus Biopharma Corporation ABUS Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties?
- Arbutus Biopharma Corporation (ABUS) reported non cash royalty revenue related to sale of future royalties of $181K in Q1 2026.
- How has Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties changed year-over-year?
- Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties decreased by 59.6% year-over-year, from $448K to $181K.
- What is the long-term trend for Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's non cash royalty revenue related to sale of future royalties has grown at a -29.8% compound annual growth rate (CAGR), from $6.11M to $1.48M.
- What does non cash royalty revenue related to sale of future royalties mean?
- This reflects revenue recognized from royalty streams that does not involve an immediate cash inflow, typically resulting from the accounting treatment of future royalty sales. It highlights the portion of reported revenue that is non-liquid and tied to long-term contractual arrangements. Investors use this to distinguish between cash-generating operations and accounting-driven revenue recognition.